Blue Bird ends joint venture with Generate Capital, appoints new executive officer
Investing.com - BTIG raised its price target on Boston Scientific (NYSE:BSX) to $132.00 from $127.00 while maintaining a Buy rating following the company’s biennial investor day in New York City. The medical device maker, currently valued at $143.79 billion, trades at a P/E ratio of 58.12x, reflecting high growth expectations. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $99 to $140.
The medical device maker set financial targets for 2026-2028 that include organic revenue compound annual growth rate (CAGR) of 10%+, operating margin expansion of approximately 50 basis points per year, double-digit adjusted earnings per share growth, and 70-80% free cash flow conversion. These ambitious targets build on the company’s strong track record, with InvestingPro showing impressive revenue growth of 21.44% over the last twelve months and an overall financial health score of "GREAT."
Boston Scientific expects its electrophysiology market to grow at a 15% CAGR over the long-range plan period, with the company anticipating above-market growth despite increasing competition in the pulsed field ablation segment. The company projects pulsed field ablation will represent 80% of approximately 1.5 million global atrial fibrillation procedures in 2028, up from 50% of 1.0 million procedures today. As a prominent player in the Healthcare Equipment & Supplies industry, the company maintains relatively low price volatility with a beta of 0.66, making it an attractive consideration for stability-focused investors.
The company’s Watchman product line for left atrial appendage closure is expected to grow at a 20% CAGR, supported by recent trial results, label expansion, and new reimbursement for concomitant procedures. Potential positive data from the Champion trial in the first half of 2026 could help expand the indicated patient population from 5 million today to 20 million by 2030.
BTIG’s new price target is based on a 35x price-to-earnings multiple applied to its 12-24 month adjusted earnings per share estimate, with the firm noting Boston Scientific has "the most comprehensive R&D and VC portfolio in MedTech that should enable durable growth well beyond 2028."
In other recent news, Boston Scientific has been the subject of multiple analyst reports and industry developments. RBC Capital reiterated its Outperform rating with a $125.00 price target for the company, while Piper Sandler maintained its Overweight rating and $115.00 price target. Piper Sandler expressed confidence in Boston Scientific’s CHAMPION-AF study, which could enhance the company’s Watchman franchise. TD Cowen also reiterated a Buy rating, setting a $115.00 price target, and anticipates the company will announce a long-range plan aiming for 10-12% sales growth through 2028. Meanwhile, Stifel has analyzed electrophysiology hospital purchasing data for the third quarter of 2025, focusing on Boston Scientific’s performance. Additionally, the Trump administration has launched a Section 232 investigation into medical devices, which may impact the medical device industry, including Boston Scientific. These developments highlight ongoing interest and potential challenges for Boston Scientific.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.